BioAge Labs (BIOA) EBT Margin (2025 - 2026)
BioAge Labs' (BIOA) quarterly EBT Margin came in at 798.92% in Q1 2026, up 9612.0% year-on-year from 8.23% in Q1 2025, and up 4.4% quarter-over-quarter from 835.71% in Q4 2025.
BioAge Labs (BIOA) EBT Margin (2025 - 2026) Analysis & Trends
BioAge Labs has disclosed EBT Margin across 2 years of filings, most recently posting 798.92% for Q1 2026.
- EBT Margin for Q1 2026 came in at 798.92%, up 9612.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 868.07% (up 403786.0% YoY), and the FY2025 annual result was 893.73%, changed N/A from the prior year.
- EBT Margin came in at 798.92% for Q1 2026 at BioAge Labs, up from 835.71% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 798.92% in Q1 2026 to a low of 979.99% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 10.97% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 33.51% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 40.73% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 25.87% |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 30.30% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 6.35% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -156.77% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -16.70% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 41.45% |
| 10 | BioAge Labs | 671.19 Mn | 288.00 Mn | -10.37 Mn | -798.92% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -798.92% |
| Dec 31, 2025 | -835.71% |
| Sep 30, 2025 | -979.99% |
| Jun 30, 2025 | -893.53% |
| Mar 31, 2025 | -895.04% |